The global AI in healthcare market was valued at USD 41.84 billion in 2025 and is estimated to surpass USD 1,136.90 billion by 2035, growing at a CAGR of 39.1% from 2026 to 2035, according to updated estimates from Acumen Research and Consulting. North America led the market with a 43% share in 2025, while Asia Pacific is projected to grow fastest, at a CAGR of 42.5% over the forecast period.
The projection implies the AI in healthcare market would expand roughly 27-fold in a decade, powered by AI-assisted diagnostics, clinical decision support, workflow automation and drug discovery. For hospitals, pharmaceutical and biotech companies, investors and technology vendors, the segment breakdown matters as much as the headline: software, cloud deployment and clinical applications hold the largest shares today, while generative AI is expected to grow the fastest.
Key Takeaways
- The AI in healthcare market was valued at USD 41.84 billion in 2025 and is forecast to exceed USD 1,136.90 billion by 2035, a CAGR of 39.1% (2026–2035).
- North America held 43% of the market in 2025, followed by Europe at 25%; Asia Pacific is the fastest-growing region at a 42.5% CAGR.
- Software accounted for 63% of the market and cloud-based deployment for 55% in 2025.
- Generative AI is the fastest-growing technology segment, with a projected 50.2% CAGR, while machine learning held a 30% share in 2025.
- Healthcare providers (46%) and clinical AI applications (42%) led their respective segments in 2025.
How Big Is the AI in Healthcare Market?
Short answer: the global AI in healthcare market was worth USD 41.84 billion in 2025 and is projected to pass USD 1,136.90 billion by 2035, a compound annual growth rate (CAGR) of 39.1% for 2026 to 2035.
| Metric | Value |
|---|---|
| Market size, 2025 | USD 41.84 billion |
| Projected market size, 2035 | More than USD 1,136.90 billion |
| CAGR, 2026–2035 | 39.1% |
| Growth multiple, 2025 to 2035 (derived) | About 27x |
| Absolute increase (derived) | About USD 1.1 trillion |
The last two rows are simple arithmetic on the published figures (1,136.90 divided by 41.84, and the difference between the two values), not separate estimates. They are included to show the scale of the projected expansion: a market that was worth tens of billions of dollars in 2025 is expected to be measured in trillions within ten years.
Which Regions Lead the AI in Healthcare Market?
Short answer: North America leads with 43% of the market, Europe is second with 25%, and Asia Pacific is the fastest-growing region at a 42.5% CAGR.
- North America (43% share in 2025): The region’s lead is attributed to advanced healthcare infrastructure and strong investments from technology giants.
- Europe (25% share in 2025): Growth is driven by healthcare digitization and government-backed innovation programs.
- Asia Pacific (42.5% projected CAGR): The fastest-growing region, fuelled by rapid healthcare modernization and government initiatives that promote AI-enabled healthcare ecosystems.
Together, North America and Europe accounted for 68% of the market in 2025 (a sum of the two published shares). Asia Pacific’s projected growth rate is 3.4 percentage points above the global CAGR of 39.1%, which points to a gradual shift in the geographic balance as the forecast period unfolds.
AI in Healthcare Market by Segment
By technology: machine learning leads, generative AI grows fastest
Machine learning held a 30% share in 2025, owing to its extensive use in disease diagnosis. Generative AI is expected to grow at the fastest rate, a CAGR of 50.2%, as healthcare organizations increasingly adopt large language models and AI-driven drug discovery platforms. That is 11.1 percentage points above the market’s overall growth rate.
By component: software dominates, services gain
Software was the leading component with a 63% share in 2025, because AI software platforms serve as the backbone of healthcare AI deployments. The services segment is expected to grow at a notable 39.1% over the forecast period as healthcare organizations seek external expertise for AI implementation.
By deployment: cloud-based systems hold the majority
The cloud-based segment dominated with a 55% share in 2025. Hospitals, government agencies and large healthcare institutions continue to prioritize data security, regulatory compliance and direct control over sensitive patient information, and those priorities are shaping how AI is deployed.
By end user: providers first, pharma and biotech second
Healthcare providers dominated with a 46% share in 2025, driven by growing adoption of AI-powered diagnostics, clinical decision support systems, patient monitoring technologies and workflow automation across hospitals and specialty care facilities. Pharmaceutical and biotechnology companies represented the second-largest segment at 22%, as AI accelerates drug discovery, clinical trial optimization, biomarker identification and precision medicine development.
By application: clinical AI ahead of administrative AI
Clinical AI dominated with a 42% share in 2025, reflecting demand for accurate disease diagnosis, personalized treatment planning, predictive healthcare analytics and improved clinical outcomes. Operational and administrative AI held the second-largest share, 20%, as organizations automate billing, claims processing, appointment scheduling, workforce management and other resource-intensive administrative functions.
What the Segment Shares Mean in Dollars
Applying each published 2025 share to the USD 41.84 billion base gives a rough sense of where revenue sits. These are derived illustrations, not separately published estimates, and segments in different categories overlap, so they should not be added together.
| Segment (2025 share) | Implied 2025 value |
|---|---|
| Software component (63%) | About USD 26.4 billion |
| Cloud-based deployment (55%) | About USD 23.0 billion |
| Healthcare providers (46%) | About USD 19.2 billion |
| North America (43%) | About USD 18.0 billion |
| Clinical AI (42%) | About USD 17.6 billion |
| Europe (25%) | About USD 10.5 billion |
| Pharma and biotech (22%) | About USD 9.2 billion |
| Operational and administrative AI (20%) | About USD 8.4 billion |
What Is Driving AI in Healthcare Market Growth?
Short answer: the main drivers are demand for more accurate diagnosis and personalized treatment, healthcare digitization backed by government programs, strong technology investment, the rise of large language models, and the need to automate administrative work.
Several threads run through the segment data. On the clinical side, providers want better diagnostics, predictive analytics and patient monitoring. On the research side, pharmaceutical and biotech firms are applying AI to drug discovery, trial optimization and biomarker identification. On the operational side, billing, claims and scheduling are prime targets for automation. Underneath all of it, the dominance of software and cloud deployment shows that the market is being built on platforms rather than standalone tools, while the expected growth in services indicates that many organizations are turning to outside specialists to implement them.
Regulatory clearance is expanding
The U.S. Food and Drug Administration says it has authorized more than 1,600 AI-enabled medical devices for marketing in the United States as of September 2026, a record that underlines how quickly AI-based products are entering clinical use. The FDA maintains a public list of these devices, which developers, hospital buyers and investors can use to track the pace of authorizations.
Regulation: States Move to Set Rules
Alongside federal device oversight, state legislatures have begun to regulate how AI is used in care and coverage decisions. A Holland & Knight review of 2026 state legislation notes that Indiana’s HB 1271 prohibits health insurers from using AI tools as the sole basis for downcoding a claim without a healthcare professional’s review. The same review describes a state law, effective October 1, 2026, that requires insurers to certify annually to the state insurance department that their use of AI does not rely on group datasets, does not discriminate against subscriber groups and is periodically monitored for accuracy.
For companies selling AI products across state lines, these rules add compliance obligations that vary by jurisdiction. They also reinforce the market’s emphasis on data security, regulatory compliance and human oversight, themes that already shape cloud deployment decisions.
What Happens Next for the AI in Healthcare Market
The forecast window runs from 2026 to 2035, and several trends are worth watching, based on the segment data and regulatory developments above. This section reflects analysis rather than published forecasts.
- Generative AI adoption. With a projected 50.2% CAGR, large language models and AI drug discovery platforms are expected to gain share from established machine learning tools.
- Asia Pacific expansion. At a 42.5% CAGR, the region is expected to narrow the gap with North America and Europe as government initiatives mature.
- Services demand. Growth in implementation and integration work may reward consultancies and vendors that can deploy AI inside complex hospital environments.
- Regulatory build-out. More state rules, and continued FDA authorizations, are likely to shape which products scale.
What the AI in Healthcare Market Means for Stakeholders
Healthcare providers are the largest buyers, with 46% of the market, and are focused on diagnostics, decision support, patient monitoring and workflow automation. Their priorities on data security and control help explain why cloud-based deployment already holds 55%.
Pharmaceutical and biotech companies account for 22% of the market and are leaning on AI to speed up discovery, trial design and biomarker work. Generative AI’s projected growth is directly relevant to this group.
Technology vendors and investors will find the largest pools of revenue in software and clinical applications today, with faster growth expected in generative AI, services and Asia Pacific.
Frequently Asked Questions About the AI in Healthcare Market
How big is the AI in healthcare market?
The global AI in healthcare market was valued at USD 41.84 billion in 2025 and is estimated to surpass USD 1,136.90 billion by 2035.
What is the CAGR of the AI in healthcare market?
The market is projected to grow at a CAGR of 39.1% from 2026 to 2035. Generative AI is expected to grow faster, at 50.2%, and Asia Pacific at 42.5%.
Which region leads the AI in healthcare market?
North America led with a 43% share in 2025, followed by Europe with 25%. Asia Pacific is projected to be the fastest-growing region.
Which segments are largest in the AI in healthcare market?
In 2025, software led by component (63%), cloud-based systems led by deployment (55%), healthcare providers led by end user (46%), and clinical AI led by application (42%).
How many AI medical devices has the FDA authorized?
The FDA says it has authorized more than 1,600 AI-enabled medical devices for U.S. marketing as of September 2026.
Sources
- Acumen Research and Consulting: AI in Healthcare Market
- U.S. FDA: Artificial Intelligence-Enabled Medical Devices
- Holland & Knight: States Continue Efforts to Regulate AI in Healthcare
Market figures are estimates and may be revised. Values labeled as derived are calculated from the published figures and are illustrative.
